Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Open-Angle Glaucoma, Unspecified Eye Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 4 Interventional

Dose, Effects and Characteristics of Pilocarpine

NCT00803803
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Pilocarpine Concentration, Pilocarpine Frequency
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 1979
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 1, 2026, 5:57 PM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

NCT03323164
View directory record Official record
Conditions
Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions
Timolol Maleate, Brimonidine Tartrate
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 1, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications
Device
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Treating Psychosocial Distress in Glaucoma

NCT06053307
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Distress, Emotional, Anxiety, Depression
Interventions
Acceptance commitment therapy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 1, 2026, 5:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

NCT05583591
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

NCT01915940
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 1, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

NCT05564091
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
Device · Procedure
Lead sponsor
Nova Eye, Inc.
Industry
Eligibility
55 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 1, 2026, 5:57 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695
View directory record Official record
Conditions
Glaucoma
Interventions
MINIject™ Implant
Device
Lead sponsor
iSTAR Medical
Industry
Eligibility
46 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
28
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 1, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Will Listening to Music Make it Easier to Take a Visual Field Test?

NCT01027039
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT00809848
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Caffeinated Coffee on Intraocular Pressure

NCT01364207
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 1, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT06822738
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
XEN63 Glaucoma Treatment System
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Culver City, California • Petaluma, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 1, 2026, 5:57 PM EDT
Active, not recruiting No phase listed Observational

Advanced Glaucoma Progression Study

NCT01742819
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

NCT02537015
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 1, 2026, 5:57 PM EDT
Completed No phase listed Observational

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

NCT02151318
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 1, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 1, 2026, 5:57 PM EDT